# clm_667CCF40E6E7

subject: Regeneron Pharmaceuticals (/record/regeneron-pharmaceuticals.md)  
predicate: quarterly_operating_income  
value: 1,223,700,000 United States dollar  
valid_from: 2022-09-30  
valid_to: 2023-03-31  
published: 2022-11-03  
recorded: 2026-11-08  
confidence: 0.95  
status: superseded  
assertable: true  
superseded_by: clm_D8EB51091FB4  
last_updated: 2026-11-08  
cite: AsOf. "Regeneron Pharmaceuticals quarterly operating income: 1,223,700,000 United States dollar", as of 2022-09-30 (until 2023-03-31). Claim clm_667CCF40E6E7, https://asof.is/claim/clm_667CCF40E6E7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000031/0001804220-22-000031-index.htm.  
checked: 2026-11-08 · parsed from the SEC filing  
parsed from: us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2022, filed 2022-11-03  

## Sources

- https://www.sec.gov/Archives/edgar/data/872589/000180422022000031/0001804220-22-000031-index.htm (primary, SEC EDGAR 10-Q Q3 FY2022, published 2022-11-03)

## Supersedes

- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_operating_income | 1,109,900,000 United States dollar | valid 2022-06-30 to 2022-09-30 | conf 0.95 | superseded | superseded_by [clm_667CCF40E6E7](/claim/clm_667CCF40E6E7.md) | [clm_C525B24D421A](/claim/clm_C525B24D421A.md)

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.